A Phase 1b Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Ibrutinib in Patients With Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary) ; Loncastuximab tesirine (Primary)
- Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions
- Sponsors ADC Therapeutics
- 30 Oct 2019 Planned End Date changed from 1 Sep 2022 to 1 Oct 2022.
- 30 Oct 2019 Planned primary completion date changed from 1 Jul 2022 to 1 Oct 2021.
- 20 Feb 2019 According to an ADC Therapeutics media release, first patient has been dosed in the trial.